- Location
Ligand Pharmaceuticals
"-
Rib-X Pharmaceuticals Has Commenced Phase 3 Trial of a Captisol-Enabled Intravenous
May 16, 2013Rib-X Pharmaceuticals, Ligand Pharmaceuticals' partner, has commenced Phase 3 trial of a Captisol-enabled intravenous (IV) formulation of delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSI). According to the ...
Tags: Rib-X, Pharmaceuticals
-
The BZA/CE Is an Investigational Therapy Developed by Wyeth Pharmaceuticals
Dec 17, 2012Pfizer and Ligand Pharmaceuticals have announced the FDA acceptance of bazedoxifene/conjugated estrogens (BZA/CE) new drug application (NDA) for review. The BZA/CE is an investigational therapy developed by Wyeth Pharmaceuticals to tackle ...
Tags: estrogens NDA, Pharmaceuticals, FDA, menopausal symptoms
-
GSK Gained FDA Priority Review Status for The Supplemental New Drug Application
Dec 7, 2012GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...
Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia
-
Onyx Pharmaceuticals Gained FDA Approval for Kyprolis for Injection
Nov 28, 2012Onyx Pharmaceuticals, a licensee of Ligand Pharmaceuticals, has gained FDA approval for Kyprolis (carfilzomib) for injection. Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have ...
Tags: Onyx Pharmaceuticals, Ligand Pharmaceuticals, Kyprolis
-
GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe
Jun 4, 2012Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...
